🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology · Phase I

Oncology programs at Phase I — ClinicalTrials.gov pipeline intelligence.

Programs
1,344

Quick answer

Oncology Phase I programs: NovaPharmaNews indexes 1,344 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 9 of 28

  1. BGB-58067

    BEONE MEDICINES AUS PTY LTD

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  2. BGB-A3055

    BEONE MEDICINES AUS PTY LTD

    Advanced Solid Tumor

    phase 1 small molecule terminated

    1 trial

  3. BGB-B2033

    BEONE MEDICINES AUS PTY LTD

    Metastatic Hepatocellular Carcinoma

    phase 1 small molecule active

    1 trial

  4. BGB-B3227

    BEONE MEDICINES AUS PTY LTD

    Advanced Cancer

    phase 1 small molecule terminated

    1 trial

  5. BGB-B455

    BEONE MEDICINES AUS PTY LTD

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  6. BGB-C354

    BEONE MEDICINES AUS PTY LTD

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  7. BGB-R046

    BEONE MEDICINES AUS PTY LTD

    Solid Tumor

    phase 1 small molecule terminated

    1 trial

  8. BGM-2121

    Chongqing Precision Biotech Co., Ltd

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  9. BI 3011441

    Boehringer Ingelheim

    Solid Tumors, KRAS Mutation

    phase 1 small molecule completed

    1 trial

  10. BI 765063

    Boehringer Ingelheim

    Head and Neck Squamous Cell Carcinoma (HNSCC)

    phase 1 small molecule active

    1 trial

  11. BI 905711

    Boehringer Ingelheim

    Gastrointestinal Neoplasms

    phase 1 small molecule completed

    1 trial

  12. BL-M07D1

    Sichuan Baili Pharmaceutical Co.,

    Breast Cancer

    phase 1 small molecule active

    1 trial

  13. BMS-641988 (AR#2)

    Bristol-Myers Squibb

    Prostate Cancer

    phase 1 small molecule completed

    1 trial

  14. BMS-906024

    Bristol-Myers Squibb

    Cancer

    phase 1 small molecule completed

    1 trial

  15. BMS-986148

    Bristol-Myers Squibb

    Advanced Cancer

    phase 1 small molecule completed

    1 trial

  16. BMS-986500

    Bristol-Myers Squibb

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  17. BNT211, BNT211, BNT211, BNT211

    BioNTech SE

    Solid Tumors

    phase 1 small molecule active

    1 trial

  18. BNT314

    BioNTech SE

    Advanced or metastatic malignant solid tumors

    phase 1 small molecule active

    1 trial

  19. BPT567

    BRIGHT MINDS BIOSCIENCES INC.

    Advanced Solid Tumors

    phase 1 small molecule terminated

    1 trial

  20. BPX-601

    Regeneron UK Limited

    Metastatic Castration-resistant Prostate Cancer

    phase 1 mab terminated

    1 trial

  21. BPX-601

    Regeneron UK Limited

    Prostate Cancer

    phase 1 gene therapy active

    1 trial

  22. BZ019

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Large B-cell Lymphoma

    phase 1 mab active

    1 trial

  23. Beamion LUNG-1: A study to test different doses of zongertinib in people with different types of advanced cancer (solid tumours with changes in the HER2 gene)

    Boehringer Ingelheim

    Solid tumours with HER2 aberrations, Non-small cell lung cancer

    phase 1 other active

    1 trial

  24. Bemarituzumab

    Prime Medicine

    Gastrointestinal Cancer

    phase 1 mab completed

    1 trial

  25. Bempegaldesleukin (NKTR-214)

    Nektar Therapeutics UK Limited

    Metastatic Melanoma

    phase 1 mab terminated

    1 trial

  26. Bexarotene (Targretin®)

    LIGAND PHARMACEUTICALS INC

    Advanced, Malignant Aerodigestive Tract Tumor (Lung, Head and Neck and Esophagus)

    phase 1 small molecule completed

    1 trial

  27. BioTTT001 injection

    Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

    Locally Advanced Breast Cancer (LABC)

    phase 1 mab terminated

    1 trial

  28. Biological/Vaccine: therapeutic autologous dendritic cells.

    LISATA THERAPEUTICS, INC.

    Kidney Cancer

    phase 1 mab terminated

    1 trial

  29. Biological: PD-1

    Hospital Authority, Hong Kong

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  30. Brentuximab Vedotin

    Takeda

    Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic

    phase 1 small molecule terminated

    1 trial

  31. C-TIL051

    Nektar Therapeutics UK Limited

    Metastatic Non Small Cell Lung Cancer

    phase 1 mab terminated

    1 trial

  32. C5951001- A Phase 1 Study of PF-08046876 in Participants with Advanced Solid Tumors.

    Pfizer Australia Pty Ltd

    advanced solid tumors

    phase 1 other active

    1 trial

  33. C6001001 - A Study to Learn about the Study Medicine PF-08052667 in People with Bladder Cancer.

    Pfizer Australia Pty Ltd

    Non-muscle invasive bladder cancer (NMIBC)

    phase 1 other active

    1 trial

  34. C6081001: A Phase 1 Study of PF-07985045 in Participants with Advanced Solid Tumors

    Pfizer Australia Pty Ltd

    KRAS mutated advanced solid tumors

    phase 1 other active

    1 trial

  35. CAN-2409 + valacyclovir

    Candel Therapeutics

    Lung Cancer

    phase 1 mab completed

    1 trial

  36. CAR T cells

    Qian Wenbin

    B-Cell Non-Hodgkin Lymphoma

    phase 1 small molecule active

    1 trial

  37. CAR T cells chimeric antigenreceptor cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

    phase 1 small molecule active

    1 trial

  38. CAR T-cell therapy

    Hospital Authority, Hong Kong

    Lymphoblastic Leukemia, Acute, Childhood

    phase 1 mab active

    1 trial

  39. CAR-T Therapy

    Zhao Weili

    Peripheral T Cell Lymphoma

    phase 1 small molecule active

    1 trial

  40. CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Relapsed Non-Hodgkin Lymphoma

    phase 1 mab active

    1 trial

  41. CAR-T cells Infusion chimeric antigen receptor T cells

    The First People's Hospital of Lianyungang

    Relapsed/Refractory Plasma Cell Leukemia

    phase 1 small molecule active

    1 trial

  42. CAR-T cells chimenric antigen receptor T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    B-Cell Non-Hodgkin Lymphoma

    phase 1 small molecule active

    1 trial

  43. CAR-T cells chimeric antigen receptor T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Relapsed/Refractory Acute Myeloid Leukemia(AML)

    phase 1 small molecule active

    1 trial

  44. CAR123 T cell treatment of relapsed/refractory hematologic malignancies.

    The George Institute

    Relapsed/refractory CD123+ hematological malignancies: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Blastic Plasmacytoid Dendritic Cell Neoplasm, Acute Lymphoblastic Leukemia.

    phase 1 other active

    1 trial

  45. CART19 cell and auto-HSCT

    Shenzhen Second People's Hospital

    Leukemia, Lymphocytic, Acute, B-Cell

    phase 1 mab active

    1 trial

  46. CART19 cells effects in patients with relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma.

    The George Institute

    Relapsed/refractory CD19+ Acute Lymphoblastic Leukaemia and Non-Hodgkin Lymphoma

    phase 1 other active

    1 trial

  47. CARTmeso CART19

    The First People's Hospital of Lianyungang

    Pancreatic Cancer

    phase 1 mab active

    1 trial

  48. CB-010

    Caribou Biosciences

    Lymphoma, Non-Hodgkin

    phase 1 gene therapy active

    1 trial

Frequently asked questions

How many oncology Phase I programs exist?

1,344 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.